BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Al Kanaani Z, Mahmud S, Kouyoumjian SP, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses. R Soc Open Sci. 2018;5:180257. [PMID: 29765698 DOI: 10.1098/rsos.180257] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Asghar MS, Rasheed U, Hassan M, Akram M, Yaseen R, Fayaz B. A CROSS-SECTIONAL SCREENING SURVEY ON THE SEROPREVALENCE OF HEPATITIS B AND HEPATITIS C AMONGST THE GENERAL POPULATION OF RURAL DISTRICTS OF SINDH, PAKISTAN. Arq Gastroenterol 2021;58:150-6. [PMID: 34231661 DOI: 10.1590/S0004-2803.202100000-26] [Reference Citation Analysis]
2 Mushtaq S, Mansoor A, Umar M, Khan A, Siddiqi S, Manzoor S. Direct-acting antiviral agents in the treatment of chronic hepatitis C-Real-life experience from clinical practices in Pakistan. J Med Virol 2020. [PMID: 32129507 DOI: 10.1002/jmv.25745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Jeong D, Karim ME, Wong S, Wilton J, Butt ZA, Binka M, Adu PA, Bartlett S, Pearce M, Clementi E, Yu A, Alvarez M, Samji H, Velásquez García HA, Abdia Y, Krajden M, Janjua NZ. Impact of HCV infection and ethnicity on incident type 2 diabetes: findings from a large population-based cohort in British Columbia. BMJ Open Diabetes Res Care 2021;9:e002145. [PMID: 34099439 DOI: 10.1136/bmjdrc-2021-002145] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Cailhol J, Khan N. Chronic hepatitis and HIV risks amongst Pakistani migrant men in a French suburb and insights into health promotion interventions: the ANRS Musafir qualitative study. BMC Public Health 2020;20:1393. [PMID: 32919467 DOI: 10.1186/s12889-020-09459-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Ayoub HH, Abu-Raddad LJ. Treatment as prevention for hepatitis C virus in Pakistan: mathematical modelling projections. BMJ Open 2019;9:e026600. [PMID: 31133586 DOI: 10.1136/bmjopen-2018-026600] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
6 Ayoub HH, Al Kanaani Z, Abu-Raddad LJ. Characterizing the temporal evolution of the hepatitis C virus epidemic in Pakistan. J Viral Hepat 2018;25:670-9. [PMID: 29345847 DOI: 10.1111/jvh.12864] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
7 Mahmud S, Chemaitelly H, Al Kanaani Z, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C Virus Infection in Populations With Liver-Related Diseases in the Middle East and North Africa. Hepatol Commun. 2020;4:577-587. [PMID: 32258952 DOI: 10.1002/hep4.1491] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Amjad U, Ahmad SQ, Mir S, Ayub M. Association of anti-HCV sero-prevalence with blood transfusion and practice of haemodialysis from multiple centres in patients on maintenance haemodialysis. Pak J Med Sci 2020;36:286-9. [PMID: 32063976 DOI: 10.12669/pjms.36.2.1343] [Reference Citation Analysis]
9 Mushtaq S, Akhter TS, Khan A, Sohail A, Khan A, Manzoor S. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan. Front Pharmacol 2020;11:550205. [PMID: 32982753 DOI: 10.3389/fphar.2020.550205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Chemaitelly H, Mahmud S, Kouyoumjian SP, Al-Kanaani Z, Hermez JG, Abu-Raddad LJ. Who to Test for Hepatitis C Virus in the Middle East and North Africa? Hepatol Commun. 2019;3:325-339. [PMID: 30859146 DOI: 10.1002/hep4.1310] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
11 Seung KJ, Franke MF, Hewison C, Huerga H, Khan U, Mitnick CD; end TB Study Group. High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients. J Hepatol 2020;72:1028-9. [PMID: 32147086 DOI: 10.1016/j.jhep.2019.10.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Khalsa JH, Mathur P. Hepatitis C Virus Infection in Persons Who Inject Drugs in the Middle East and North Africa: Intervention Strategies. Viruses 2021;13:1363. [PMID: 34372569 DOI: 10.3390/v13071363] [Reference Citation Analysis]
13 Mahnoor, Noreen M, Imran M, Safi SZ, Bashir MA, Alkhuriji AF, Alomar SY, Alharbi HM. Association of blood groups with hepatitis C viremia. Saudi J Biol Sci 2021;28:5359-63. [PMID: 34466115 DOI: 10.1016/j.sjbs.2021.05.062] [Reference Citation Analysis]
14 Hedayati-Moghaddam MR, Soltanian H, Ahmadi-Ghezeldasht S. Occult hepatitis C virus infection in the Middle East and Eastern Mediterranean countries: A systematic review and meta-analysis. World J Hepatol 2021; 13(2): 242-260 [PMID: 33708353 DOI: 10.4254/wjh.v13.i2.242] [Reference Citation Analysis]
15 Botheju WSP, Zghyer F, Mahmud S, Terlikbayeva A, El-Bassel N, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses. Sci Rep 2019;9:2090. [PMID: 30765844 DOI: 10.1038/s41598-019-38853-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Jafri W, Kamran M. Hepatocellular Carcinoma in Asia: A Challenging Situation. Euroasian J Hepatogastroenterol 2019;9:27-33. [PMID: 31988864 DOI: 10.5005/jp-journals-10018-1292] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
17 Akhtar S, Nasir JA, Hinde A. The prevalence of hepatitis C virus infection in β-thalassemia patients in Pakistan: a systematic review and meta-analysis. BMC Public Health 2020;20:587. [PMID: 32349737 DOI: 10.1186/s12889-020-8414-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Khan A, Nawaz M, Ullah S, Rehman IU, Khan A, Saleem S, Zaman N, Shinwari ZK, Ali M, Wei DQ. Core amino acid substitutions in HCV-3a isolates from Pakistan and opportunities for multi-epitopic vaccines. J Biomol Struct Dyn 2022;40:3753-68. [PMID: 33246391 DOI: 10.1080/07391102.2020.1850353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Ullah N, Kakakhel MA, Bai Y, Xi L, Khan I, Kalra BS, Kumar T, Ahmad H, Shah M, Guanlan L, Zhang C. Prevalence of active HCV infection and genotypic distribution among the general population of district Mardan, Pakistan. Braz J Biol 2021;83:e244977. [PMID: 34287506 DOI: 10.1590/1519-6984.244977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Butt N, Muhammad I, Abou Bakr A, Akhtar Z, Ali M, Syed Muhammad S, Maheshwary N. Efficacy and Safety of Sofosbuvir-Velpatasvir combination in Hepatitis C Virus-infected Pakistani Patients without Cirrhosis or with Compensated Cirrhosis: A Prospective, Open-label Interventional Trial. Cureus 2020;12:e6537. [PMID: 32042516 DOI: 10.7759/cureus.6537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Ishtiaq A, Shah S, Iftikhar S, Baig-Ansari N, Ashraf H. Relationship of FIB-4 index with transient elastography in chronic hepatitis C patients having APRI ≥ 0.5 - ≤2 in a resource-limited setting in Pakistan. J Family Med Prim Care 2020;9:5564-73. [PMID: 33532396 DOI: 10.4103/jfmpc.jfmpc_1294_20] [Reference Citation Analysis]
22 Mahmud S, Kouyoumjian SP, Al Kanaani Z, Chemaitelly H, Abu-Raddad LJ. Individual-level key associations and modes of exposure for hepatitis C virus infection in the Middle East and North Africa: a systematic synthesis. Ann Epidemiol 2018;28:452-61. [PMID: 29661680 DOI: 10.1016/j.annepidem.2018.03.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
23 Dumaidi K, Al-Jawabreh A, Samarah F, Rabayaa M. Prevalence of Sero-Molecular Markers of Hepatitis C and B Viruses among Patients with β-Thalassemia Major in Northern West Bank, Palestine. Can J Infect Dis Med Microbiol 2018;2018:1039423. [PMID: 30254711 DOI: 10.1155/2018/1039423] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 Lim AG, Scott N, Walker JG, Hamid S, Hellard M, Vickerman P. Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis. PLoS Med 2021;18:e1003818. [PMID: 34665815 DOI: 10.1371/journal.pmed.1003818] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Mahmud S, Chemaitelly HS, Kouyoumjian SP, Al Kanaani Z, Abu-Raddad LJ. Key associations for hepatitis C virus genotypes in the Middle East and North Africa. J Med Virol 2020;92:386-93. [PMID: 31663611 DOI: 10.1002/jmv.25614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
26 Salari N, Kazeminia M, Hemati N, Ammari-Allahyari M, Mohammadi M, Shohaimi S. Global prevalence of hepatitis C in general population: A systematic review and meta-analysis. Travel Med Infect Dis 2022;46:102255. [PMID: 35007756 DOI: 10.1016/j.tmaid.2022.102255] [Reference Citation Analysis]
27 Ehsan H, Wahab A, Anwer F, Iftikhar R, Yousaf MN. Prevalence of Transfusion Transmissible Infections in Beta-Thalassemia Major Patients in Pakistan: A Systematic Review. Cureus 2020;12:e10070. [PMID: 32874814 DOI: 10.7759/cureus.10070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Mahmud S, Mumtaz GR, Chemaitelly H, Al Kanaani Z, Kouyoumjian SP, Hermez JG, Abu-Raddad LJ. The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. Addiction 2020;115:1244-62. [PMID: 32009283 DOI: 10.1111/add.14944] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
29 Mahmud S, Al Kanaani Z, Abu-Raddad LJ. Characterization of the hepatitis C virus epidemic in Pakistan. BMC Infect Dis 2019;19:809. [PMID: 31521121 DOI: 10.1186/s12879-019-4403-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
30 Khan UI, Qureshi A, Lal K, Ali S, Barkatali A, Nayani S. Implementation and evaluation of Employee Health and Wellness Program using RE-AIM framework. IJWHM 2021;15:87-98. [DOI: 10.1108/ijwhm-04-2021-0081] [Reference Citation Analysis]
31 Deress T, Million Y, Belachew T, Jemal M, Girma M. Seroprevalence of Hepatitis C Viral Infection in Ethiopia: A Systematic Review and Meta-Analysis. ScientificWorldJournal 2021;2021:8873389. [PMID: 33897305 DOI: 10.1155/2021/8873389] [Reference Citation Analysis]
32 Mahmud S, Chemaitelly H, Alaama AS, Hermez JG, Abu-Raddad L. Hepatitis C virus among blood donors and general population in Middle East and North Africa: Meta-analyses and meta-regressions. World J Meta-Anal 2022; 10(1): 12-24 [DOI: 10.13105/wjma.v10.i1.12] [Reference Citation Analysis]
33 Lin B, Liu K, Qiu Y. Preparation of modified polysulfone material decorated by sulfonated citric chitosan for haemodialysis and its haemocompatibility. R Soc Open Sci 2021;8:210462. [PMID: 34540249 DOI: 10.1098/rsos.210462] [Reference Citation Analysis]
34 Rao JR, Rafique S, Ali A, Rehman G, Ilyas M, Idrees M. Next-generation sequencing studies on the E1-HVR1 region of hepatitis C virus (HCV) from non-high-risk HCV patients living in Punjab and Khyber Pakhtunkhwa, Pakistan. Arch Virol 2021;166:3049-59. [PMID: 34448937 DOI: 10.1007/s00705-021-05203-x] [Reference Citation Analysis]
35 Akhtar S, Nasir JA, Usman M, Sarwar A, Majeed R, Billah B. The prevalence of hepatitis C virus in hemodialysis patients in Pakistan: A systematic review and meta-analysis. PLoS One 2020;15:e0232931. [PMID: 32407423 DOI: 10.1371/journal.pone.0232931] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Wood S, Harrison SE, Judd N, Bellis MA, Hughes K, Jones A. The impact of behavioural risk factors on communicable diseases: a systematic review of reviews. BMC Public Health 2021;21:2110. [PMID: 34789209 DOI: 10.1186/s12889-021-12148-y] [Reference Citation Analysis]
37 Khaliq S, Raza SM. Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan. Medicina (Kaunas) 2018;54:E80. [PMID: 30400604 DOI: 10.3390/medicina54050080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
38 Mahmud S, Al-Kanaani Z, Chemaitelly H, Chaabna K, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C virus genotypes in the Middle East and North Africa: Distribution, diversity, and patterns. J Med Virol. 2018;90:131-141. [PMID: 28842995 DOI: 10.1002/jmv.24921] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
39 Alhassan RK, Adu-gyamfi BA, Oliver A, Ayensu B, Awoenam G, Angela O, Nketiah-amponsah E, Mwini-nyaledzigbor PP. Correlates of Patients’ Preference for Therapeutic Injections in a Major Regional Referral Hospital in Ghana: Implications for Policy and Clinical Practice. SAGE Open 2018;8:215824401880458. [DOI: 10.1177/2158244018804583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Waheed U, Abdella YE, Saba NE, Arshad M, Wazeer A, Farooq A, Usman J, Arshad A, Zaheer HA. Evaluation of screening effectiveness of hepatitis B surface antigen and anti-HCV rapid test kits in Pakistan. J Lab Physicians 2019;11:369-72. [PMID: 31929706 DOI: 10.4103/JLP.JLP_172_19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
41 Ahmad S, Shahid F, Tahir Ul Qamar M, Rehman HU, Abbasi SW, Sajjad W, Ismail S, Alrumaihi F, Allemailem KS, Almatroudi A, Ullah Saeed HF. Immuno-Informatics Analysis of Pakistan-Based HCV Subtype-3a for Chimeric Polypeptide Vaccine Design. Vaccines (Basel) 2021;9:293. [PMID: 33801143 DOI: 10.3390/vaccines9030293] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]